SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 342 filers reported holding SAREPTA THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.71 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $487,910,500 | -7.9% | 4,025,000 | -13.0% | 7.61% | +5.8% |
| Q2 2023 | $529,985,734 | +4.6% | 4,627,888 | +18.7% | 7.19% | -4.3% |
| Q1 2023 | $506,754,500 | +23.2% | 3,900,000 | +22.8% | 7.51% | +22.2% |
| Q4 2022 | $411,416,500 | +17.2% | 3,175,000 | 0.0% | 6.15% | -5.2% |
| Q3 2022 | $350,965,000 | +38.1% | 3,175,000 | -6.3% | 6.48% | +29.1% |
| Q2 2022 | $254,114,000 | +3.8% | 3,390,000 | +8.1% | 5.02% | +12.3% |
| Q1 2022 | $244,906,000 | -13.9% | 3,135,000 | -8.5% | 4.47% | -7.6% |
| Q4 2021 | $284,316,000 | +21.8% | 3,425,000 | +26.9% | 4.84% | +32.0% |
| Q3 2021 | $233,394,000 | +25.1% | 2,700,000 | +12.5% | 3.67% | +12.9% |
| Q2 2021 | $186,576,000 | +16.4% | 2,400,000 | +11.6% | 3.25% | +17.3% |
| Q1 2021 | $160,240,000 | -46.3% | 2,150,000 | +22.9% | 2.77% | -46.1% |
| Q4 2020 | $298,358,000 | +26.8% | 1,750,000 | +4.5% | 5.14% | +53.7% |
| Q3 2020 | $235,220,000 | -12.4% | 1,675,000 | 0.0% | 3.34% | -37.1% |
| Q2 2020 | $268,570,000 | +73.2% | 1,675,000 | +5.7% | 5.31% | +1.5% |
| Q1 2020 | $155,045,000 | -31.7% | 1,585,000 | -9.9% | 5.23% | -21.5% |
| Q4 2019 | $227,110,000 | +79.7% | 1,760,000 | +4.9% | 6.67% | +26.5% |
| Q3 2019 | $126,387,000 | -42.1% | 1,678,000 | +1.7% | 5.27% | -30.1% |
| Q2 2019 | $218,193,000 | +53.2% | 1,650,000 | +38.1% | 7.54% | +22.5% |
| Q1 2019 | $142,432,000 | +2.4% | 1,195,000 | -6.3% | 6.16% | -26.0% |
| Q4 2018 | $139,141,000 | -8.7% | 1,275,000 | +35.1% | 8.32% | +18.9% |
| Q3 2018 | $152,385,000 | +20.2% | 943,500 | -1.6% | 7.00% | +43.4% |
| Q2 2018 | $126,751,000 | +347.4% | 958,928 | -17.4% | 4.88% | -14.7% |
| Q4 2016 | $28,328,000 | -68.6% | 1,160,300 | -29.1% | 5.72% | -63.8% |
| Q3 2016 | $90,161,000 | +185.9% | 1,635,509 | -51.5% | 15.82% | +125.7% |
| Q2 2016 | $31,539,000 | +28.5% | 3,368,790 | +130.3% | 7.01% | -18.2% |
| Q1 2016 | $24,552,000 | +22.6% | 1,462,500 | +165.8% | 8.56% | +24.1% |
| Q4 2015 | $20,032,000 | +22.9% | 550,307 | -15.0% | 6.90% | +62.9% |
| Q3 2015 | $16,297,000 | – | 647,325 | – | 4.24% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ikarian Capital, LLC | 399,400 | $35,962,000 | 5.36% |
| Avoro Capital Advisors LLC | 3,125,000 | $281,406,000 | 4.79% |
| Varenne Capital Partners | 324,661 | $29,236,000 | 4.34% |
| Evolutionary Tree Capital Management, LLC | 96,695 | $8,707,000 | 4.18% |
| Ally Bridge Group (NY) LLC | 120,000 | $10,806,000 | 3.78% |
| Casdin Capital, LLC | 1,350,000 | $121,568,000 | 3.43% |
| Ghost Tree Capital, LLC | 100,000 | $9,005,000 | 3.23% |
| GREAT POINT PARTNERS LLC | 145,405 | $13,094,000 | 2.91% |
| Camber Capital Management LP | 825,000 | $74,291,000 | 2.55% |
| Alpha DNA Investment Management LLC | 17,522 | $1,577,000 | 1.00% |